Loading clinical trials...
Loading clinical trials...
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
Conditions
Interventions
pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
laboratory biomarker analysis
Locations
1
United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
March 6, 2012
Primary Completion Date
January 9, 2015
Completion Date
December 1, 2020
Last Updated
February 25, 2021
NCT02122185
NCT01846520
NCT00041080
NCT00466960
NCT01155258
NCT00390234
Lead Sponsor
University of Washington
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions